Indivior stock holds mid-cap valuation as investors watch latest guidance
Published on 08/27/2026 at 12:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Indivior (GB00BYZ0C031) stock is trading in the mid-$30s per share as of August 26, 2026, leaving the specialty pharmaceuticals group with a multibillion-dollar market value on its Nasdaq listing. A recent quote shows the shares at $35.79, giving the company a market capitalization of $4.49 billion based on the latest available data from late August 2026 a recent share price overview and a separate quote snapshot.
Indivior stock trades in the mid-$30s
According to late-session market data as of August 26, 2026, Indivior shares changed hands at $35.79 on Nasdaq, slightly below a recent daily high of $36.19 and within a day range of $35.64 to $36.19 detailed intraday trading data. The same data set indicates that earlier in August 2026 the stock closed the month at $36.19, down 9.62% from an opening level of $39.94 for the month, illustrating a pullback over the period for investors tracking short-term performance monthly return figures.
The most recent quote-feed snapshot from another market portal points to a spot price of $35.99 for Indivior, with the stock trading between an intraday low of $35.99 and a high of $36.15 on August 26, 2026, and a current trading volume of 1,820 shares compared with an average daily volume of 2.02 million a trading volume overview. Using that quote, the same dataset calculates Indivior’s market capitalization at $4.49 billion and a price-to-earnings ratio of 12.85 as of the latest trading session, placing the stock in a mid-cap bracket with what appears to be a moderate earnings multiple a valuation snapshot.
Valuation, 52-week range and analyst expectations
A separate equity overview shows that as of August 5, 2026, Indivior’s shares closed at $38.73, with a prior close of $36.50 in that session and a daily trading range between $36.28 and $39.44 Indivior price history and 52-week range. The same source highlights a 52-week trading range from $21.48 to $42.81, placing the recent late-August quote of $35.79 below the recent 12-month peak but well above the lows, giving context for investors evaluating where the current level sits within the past year’s fluctuations.
For investors focusing on forward-looking expectations, the same equity analysis source cites a 12-month average target price of $49.75 for Indivior shares, with individual estimates spanning from a low of $46 to a high of $53 an analyst target overview. Based on the late-August 2026 trading price of $35.79, that average target would imply an upside gap of $13.96 per share, or 39.0%, if the stock were to reach the consensus level, though investors will weigh this against the company’s execution on its pipeline and legal or regulatory risks.
The same dataset also reports that at the close on August 5, 2026, Indivior’s last quoted after-hours price stood at $38.99, down $0.26 or 0.67% from the regular-session close after-hours quotation details. Combined with the August monthly change figure of negative 9.62% from an opening level of $39.94 to a late-month level of $36.19, the data underline that recent trading has seen some volatility as the stock has moved away from its recent highs.
Institutional ownership and liquidity context
In addition to price-action metrics, the same equity analysis source provides an overview of Indivior’s shareholder base, indicating that institutional investors and funds hold the bulk of the stock a shareholder structure overview. One table shows that funds and exchange-traded products collectively hold 53.92 million shares, representing 44.23% of shares outstanding with a market value of $2.015 billion, while other institutional investors hold 92.26 million shares, or 55.77% of the total, valued at $3.448 billion as of the latest reporting snapshot an institutional holdings breakdown.
In total, the same figures indicate that Indivior has 146.18 million shares outstanding, representing a total equity market value of $5.463 billion at the referenced price levels total shares and market value data. For investors, that share count and ownership mix helps to frame daily volume metrics, such as the 37,822 shares traded in the August 26, 2026 session cited in another data source, as a relatively modest proportion of the overall float daily volume details.
Business focus on opioid-dependence treatments
Indivior’s strategic focus remains centered on treatments for opioid dependence and related psychiatric conditions, with its flagship buprenorphine-based therapies targeting the management of opioid use disorder. The company’s product portfolio includes long-acting formulations and sublingual medications that seek to improve adherence and reduce misuse risks for patients undergoing treatment.
Beyond core opioid-dependence medications, Indivior is working on pipeline assets addressing broader addiction and mental-health markets. These initiatives include investigational therapies for alcohol use disorder and other substance-use conditions, areas where the company sees unmet medical need and potential for long-term revenue diversification as regulatory approvals and reimbursement decisions progress over the next several years.
Stock positioning for investors
Taking the recent figures together, Indivior stock currently trades at $35.79 as of August 26, 2026, against a 52-week high of $42.81 and a 52-week low of $21.48, leaving the current price 16.4% below the recent high and 66.6% above the 12-month low Indivior 52-week range positioning. With a market capitalization figure in the $4.49 billion to $5.46 billion range based on different late-August datasets and a reported price-to-earnings ratio of 12.85 as of August 26, 2026, the stock presents a valuation profile that investors can compare to other specialty pharmaceutical names PE and market cap metrics.
For retail investors, the key numerical signals currently visible are the stock’s retreat of 9.62% during August 2026 from an opening mark of $39.94 to a late-month level of $36.19, the 52-week span between $21.48 and $42.81, and the gap between the late-August trading price of $35.79 and the cited 12-month average target of $49.75 August 2026 performance data consensus target comparison. How those numbers align with each investor’s risk tolerance and view on Indivior’s pipeline and legal or regulatory landscape will shape individual decisions on the stock.
